Minerva Neurosciences Stock News

Zacks Investment Research cut shares of Minerva Neurosciences (NASDAQ:NERV) from a buy rating to a hold rating in a research report sent to investors on Tuesday, Zacks.com reports. According to Zacks, Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of a portfolio of product candidates to treat [] The post Zacks Investment Research Downgrades Minerva Neurosciences (NASDAQ:NERV) to Hold appeared first on ETF Daily News .

Zacks Investment Research upgraded shares of Minerva Neurosciences (NASDAQ:NERV) from a hold rating to a buy rating in a research report released on Wednesday morning, Zacks.com reports. They currently have $1.25 target price on the biopharmaceutical company’s stock. According to Zacks, “Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. It is focused on the development […]

Zacks Investment Research downgraded shares of Minerva Neurosciences (NASDAQ:NERV) from a buy rating to a hold rating in a research report sent to investors on Tuesday morning, Zacks.com reports. According to Zacks, Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of a portfolio of product candidates to []

Minerva Neurosciences Inc. (NASDAQ:NERV)s traded shares stood at 0.32 million during the last session, with the companys beta value hitting 0.88. At the close of trading, the stocks price was $1.12, to imply a decrease of -5.08% or -$0.06 in intraday trading. The NERV shares 52-week high remains $4.11, putting it -266.96% down since that Minerva Neurosciences Inc. (NASDAQ: NERV) Plunged -63.04% In 6 Months Heres What Happens Next Read More »

Zacks Investment Research upgraded shares of Minerva Neurosciences (NASDAQ:NERV) from a hold rating to a buy rating in a research report released on Thursday morning, Zacks.com reports. Zacks Investment Research currently has $1.50 target price on the biopharmaceutical company’s stock. According to Zacks, “Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. It is focused on […]

Minerva Neurosciences (NASDAQ:NERV) was upgraded by Zacks Investment Research from a hold rating to a buy rating in a report released on Friday, Zacks.com reports. The firm currently has a $1.50 target price on the biopharmaceutical companys stock. Zacks Investment Researchs target price would suggest a potential upside of 14.50% from the companys current price. []

Minerva Neurosciences, Inc. (NERV) CEO Remy Luthringer on Q3 2021 Results - Earnings Call Transcript

Minerva Neurosciences (NERV) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the st

Management to Host Conference Call Management to Host Conference Call

Frederick Ahlholm is Named Chief Financial Officer as Company Prepares to Submit a Pre-NDA Meeting Request to FDA

Minerva Neurosciences Inc (NASDAQ: NERV) announced results from a bioequivalence study comparing roluperidone formulations used in Phase 2b and Phase 3 trials and the planned commercial formulation

Company to Request Pre-NDA Meeting with U.S. Food and Drug Administration Company to Request Pre-NDA Meeting with U.S. Food and Drug Administration

Investors need to pay close attention to Minerva Neurosciences (NERV) stock based on the movements in the options market lately.

Minerva Neurosciences, Inc. (NERV) CEO Remy Luthringer on Q2 2021 Results - Earnings Call Transcript

Minerva Neurosciences (NERV) delivered earnings and revenue surprises of -47.06% and -100.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock